
NanoViricides Seeks Rare Pediatric Disease Designation for Measles Treatment Candidate
NanoViricides has filed with the FDA for Rare Pediatric Disease Drug designation for its broad-spectrum antiviral NV-387 as a measles treatment, potentially qualifying for regulatory incentives in a market lacking approved therapies.
Read full story


























